Minoxidil
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Minoxidil: From Hypertension and Alopecia to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Minoxidil was originally used to treat hypertension (as an oral vasodilator) and hair loss (as a topical hair-growth stimulant). The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, a rare hereditary hair loss disorder. Currently no clinical trials are registered, and 3 publications (all case reports) support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertensive disorder, hypertension, alopecia (from the knowledge graph; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | Hold (treat as a research question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, minoxidil is an established hair-growth stimulant. Its sulfate metabolite is thought to open potassium channels, prolong the anagen (growth) phase of the hair cycle and cause vasodilation. Its efficacy in common hair loss (alopecia) is well established.
Hypotrichosis simplex of the scalp is a rare inherited form of hair loss, linked to variants in the CDSN gene, which encodes the desmosome protein corneodesmosin. Because minoxidil acts on the hair follicle cycle in general, applying it to this condition is mechanistically plausible. However, the three available reports mostly combine minoxidil with other treatments (growth factors, botanical extracts, platelet-rich plasma), so the effect of minoxidil alone cannot be isolated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35761391 | 2022 | Case report/series | Dermatologic Therapy | Hereditary hypotrichosis simplex of the scalp treated with oral minoxidil plus growth factors |
| 39902296 | 2024 | Case report | Frontiers in Genetics | Familial case in an 8-year-old boy with a CDSN mutation, treated with botanical extracts plus minoxidil |
| 36651821 | 2023 | Case report | Journal of Dermatological Treatment | 14-year-old patient treated with platelet-rich plasma injection plus topical minoxidil 2%, reported as a successful treatment |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08213P | REGAINE Extra Strength (5%) | Solution | Not specified in the records |
| SIN10301P | GROWELL SCALP LOTION 2% w/v | Lotion | Not specified in the records |
| SIN04399P | REGAINE Regular Strength (2%) | Solution | Not specified in the records |
| SIN09083P | GROWELL SCALP LOTION 3% w/v | Lotion | Not specified in the records |
| SIN08987P | REGRO LOTION 5% | Lotion | Not specified in the records |
All 8 registered products are single-ingredient topical solutions or lotions and are currently valid.
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from drug-disease relationships, not from package insert text): cardiovascular conditions such as myocardial infarction, heart disease, stroke and cerebrovascular disorders; pericardial conditions (pericarditis, pericardial effusion, cardiac tamponade); orthostatic hypotension and related autonomic disorders; kidney disease; phaeochromocytoma and related adrenal or paraganglionic tumours; hemoglobinopathy; and scalp dermatosis.
- Drug Interactions: The interaction screen returned 100 records. Those listed are mostly of moderate severity, including corticosteroids (hydrocortisone, prednisone, dexamethasone, betamethasone, triamcinolone, budesonide, prednisolone), SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), opioids (morphine, opium), bupropion, dronabinol, nabilone and sapropterin.
Package insert warnings and contraindications have not yet been reviewed. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link is plausible and the TxGNN score is very high. However, the supporting evidence consists only of three case reports, mostly using combination regimens, with no registered trials. Minoxidil's own contribution cannot be isolated, so this is best treated as a research question rather than a ready candidate.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Controlled or larger series evaluating minoxidil alone in hereditary hypotrichosis simplex
- Review of the approved indication text for the Singapore products and the suitability of topical versus low-dose oral use, including cardiovascular risk screening for oral use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.